Pfizer’s (PFE) Overweight Rating Reiterated at Cantor Fitzgerald
Cantor Fitzgerald reaffirmed their overweight rating on shares of Pfizer (NYSE:PFE – Free Report) in a report published on Monday, Benzinga reports. They currently have a $45.00 price target on the biopharmaceutical company’s stock. A number of other brokerages have also recently commented on PFE. UBS Group increased their price target on Pfizer from $30.00 […]
More Stories
Virpax Pharmaceuticals Receives Nasdaq Panel Decision, Granted Listing Continuation with Conditions
On January 6, 2025, Virpax Pharmaceuticals, Inc. announced in a Form 8-K filing that it had received a decision from...
Mangoceuticals (NASDAQ:MGRX) Enters into Securities Purchase Agreements with Institutional Investors
Dallas, Texas, January 8, 2025 – Mangoceuticals, Inc. (NASDAQ:MGRX) recently disclosed in a Form 8-K filing with the Securities and...
**MedTech Acquisition Announces Leadership Transition and Salary Investment Program**
MedTech Acquisition (OTCMKTS:MTACU) recently disclosed its current report with the Securities and Exchange Commission (SEC) dated January 4, 2025. The...
CJM Wealth Advisers Ltd. Raises Stock Holdings in The Home Depot, Inc. (NYSE:HD)
CJM Wealth Advisers Ltd. boosted its holdings in The Home Depot, Inc. (NYSE:HD – Free Report) by 4.8% during the...
Eagle Point Income (NYSE:EIC) Upgraded at B. Riley
B. Riley upgraded shares of Eagle Point Income (NYSE:EIC – Free Report) to a strong-buy rating in a research note...
Burlington Stores (NYSE:BURL) Stock Rating Upgraded by UBS Group
Burlington Stores (NYSE:BURL – Get Free Report) was upgraded by research analysts at UBS Group from a “neutral” rating to...